Hmmm

Antibiotics for irritable bowel syndrome? I suppose the biological plausibility argument would be that IBS is a result either of bacterial overgrowth or of an as-yet-unidentified pathogen that is responsive to rifaximin. I haven't been following this literature at all, but my understanding is that other antibiotic trials have not been fruitful (at least for long term alleviation of symptoms), so before I run with an abstract about a study funded by the makers of the drug, I'd like to see more data--starting with the results of this trial being published in a peer-reviewed journal.